Help guide our efforts to modernize
Send us your comments by March 14, 2020. Menu

Aripiprazole Oral Solution in the Treatment of Children and Adolescents With Autistic Disorder

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03487770
Recruitment Status : Enrolling by invitation
First Posted : April 4, 2018
Last Update Posted : January 22, 2020
Information provided by (Responsible Party):
Otsuka Beijing Research Institute

Brief Summary:
This is a multicenter, randomized, double-blind, placebo-controlled, parallel-group study to assess the efficacy, safety, tolerability and the steady-state plasma trough concentration of aripiprazole flexible-dosed in children and adolescents with a diagnosis of Autistic Disorder. Approximately 100 subjects will be randomly assigned at a 1:1 ratio to receive aripiprazole (2 to 15 mg) or placebo treatment for 8 weeks

Condition or disease Intervention/treatment Phase
Autistic Disorder Drug: Aripiprazole Oral Solution Drug: Placebo Oral Solution Phase 3

Detailed Description:

Screening Phase: up to 42 days (consisting of a Screening Visit (V1), a washout period and Interim Screening Visit (V1a) when applicable, and a Baseline Visit (V2). The Screening Phase will serve multiple purposes: to allow for appropriate washout of prohibited medications; to allow for review of screening data; to establish a pre-treatment baseline of key outcome measures.

Treatment Phase: The duration of the treatment is 8 weeks. The purpose of the treatment phase is to evaluate the efficacy, safety, tolerability and steady-state plasma trough concentration of aripiprazole in the treatment of serious behavioral problems in children and adolescents with a diagnosis of Autistic Disorder..

Safety Follow-up Phase: All subjects will be followed up for safety (adverse events) at Day 16 after the last medication via telephone.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-blind, Flexible-dosed, Placebo-controlled, Parallel-group Clinical Trial Evaluating the Efficacy and Safety of Aripiprazole Oral Solution in Children and Adolescents With Autistic Disorder
Actual Study Start Date : April 9, 2018
Estimated Primary Completion Date : April 2020
Estimated Study Completion Date : April 2020

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Aripiprazole Oral Solution
1 mg/mL, 2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals;
Drug: Aripiprazole Oral Solution
Aripiprazole 2~15 mg/day (2~15 mL/day)
Other Names:
  • Abilify
  • Aripiprazole

Placebo Comparator: Placebo Oral Solution
2 ~ 15 mg/day (2 ~ 15 mL/day), taken once daily for 8 weeks. Administrate about at the same time each day, either before or after meals.
Drug: Placebo Oral Solution
Placebo 2~15 mg/day (2~15 mL/day)
Other Name: Placebo

Primary Outcome Measures :
  1. Changes from Baseline to Week 8 (or endpoint) in the ABC-I score [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The objective of the primary analysis is to compare the efficacy of aripiprazole flexible-dosed (2 ~ 15 mg/day) with placebo in reducing serious behavioral problems, specifically irritability, agitation and self-injurious behavior, in children and adolescents with a diagnosis of Autistic Disorder. The efficacy is assessed by assessed by change from baseline to endpoint on the Irritability Subscale of the ABC (ABC-I).

Secondary Outcome Measures :
  1. Clinician-rated CGI-I score at Week 8 (or endpoint) [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The efficacy is assessed by the clinician-rated CGI-I score at Week 8

  2. Change in ABC subscale scores from Baseline to Week 8 (or endpoint) [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The efficacy is assessed by changes from Baseline to Week 8 (or endpoint) in Social Withdrawal, Hyperactivity, Stereotypy and Inappropriate Speech Subscale scores of the ABC

  3. Response Rate at Week 8 (or endpoint) (or endpoint) [ Time Frame: Baseline and 8 weeks (or endpoint) ]
    The response is defined as a reduction ≥25% in ABC-I score compared to the baseline, and a CGI-I score of much improved or very much improved) at Week 8 (or endpoint).The efficacy is assessed by response rate at Week 8 (or endpoint).

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   6 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Written informed consent must be obtained from a legally authorized guardianprior to the initiation of any protocol-required procedures.
  2. The subject and/or the designated guardian(s) or caregiver(s) are able to comprehend and satisfactorily comply with the protocol requirements, in the opinion of the Investigator.
  3. The patient meets current DSM-IV-TR diagnostic criteria for Autistic Disorder and also demonstrates behaviors such as tantrums, aggression, self-injurious behavior, or a combination of these problems. In addition, the Childhood Autism Rating Scale (CARS) score is ≥30.
  4. The subject has a Clinical Global Impressions-Severity (CGI-S) score ≥ 4 AND an ABC-I subscale score ≥18 at screening (Visit 1 or Visit 1a) and baseline (V2).
  5. Environmental factors can be consistent throughout the trial period.
  6. The subject is a male or female child or adolescent 6 to 17 years of age (6 ≤ age ≤ 17) at Baseline (V2).

Exclusion Criteria:

  1. Women of childbearing potential (WOCBP) who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 8 weeks after the study.

    Note: WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea 12 consecutive months; or women on hormone replacement therapy with documented serum follicle stimulating hormone level ≥ 35 mIU/mL].

  2. Women with a positive pregnancy test or who are pregnant or breastfeeding.
  3. The subject has a current diagnosis of psychotic disorder such as bipolar disorder, schizophrenia, or depression.
  4. The subject is currently diagnosed with another disorder on the autism spectrum, including Pervasive Developmental Disorder-Not Otherwise Specified, Asperger's Disorder, Rett's Disorder, Childhood Disintegrative Disorder or Fragile-X Syndrome.
  5. The subject has a history of neuroleptic malignant syndrome.
  6. The subject represents a significant risk of committing suicide based on history or routine psychiatric status examination.
  7. The subject has had a seizure in the past year or the electroencephalograph examination is epileptiform discharge at screening.
  8. The subject has a history of severe head trauma or stroke;
  9. The subject has a history or current evidence of any unstable medical conditions (eg. history of congenital heart disease or arrhythmia, or cancer) that, in the judgment of the investigator would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial.
  10. Non-pharmacological therapy (e.g., psychotherapy, behavior modification, and education training, etc.) could not be stable prior to screening and consistent throughout the study, and the subject who needs to use acupuncture and moxibustion, auditory integration, biofeedback and transcranial magnetic stimulation therapy as supplemental replacement therapy in 7 days prior to taking investigational product or during the course of the trial.
  11. The subject is considered treatment resistant to antipsychotics medication, in the opinion of the Investigator, based on lack of therapeutic response to 2 different antipsychotics with reasonable doses after treatment of at least 3 weeks each.
  12. The subjects considered treatment resistant to aripiprazole in the opinion of the investigator based on lack of therapeutic response to an adequate dose and duration of aripiprazole treatment.
  13. The following laboratory test results, vital sign and Electrocardiograph (ECG) findings are exclusionary:

    • QTc > 450 msec (male), QTc > 470 msec (female)
    • Platelets (below the lower limit)
    • Hemoglobin (below the lower limit)
    • Neutrophils (below the lower limit)
    • AST (SGOT) or ALT (SGPT) (above the upper limit)
    • Creatinine (above the upper limit) In addition, subjects should be excluded if they have any other abnormal laboratory test result, vital sign result or ECG finding that in the investigator's judgment is clinically significant, in that it would impact the safety of the patient or the interpretation of the study results.
  14. The subject weighs < 15 kg.
  15. The subject has a known allergy or hypersensitivity to aripiprazole or other dihydrocarbostyrils (eg. carteolol, vesnarinone, and cilostazol).
  16. The subject has participated in any clinical trials with an investigational agent within the past month.
  17. Subjects who are likely to require prohibited concomitant therapy during the trial (refer to Section 7 Prohibited and Restricted Therapies).
  18. Subjects who participated in a previous clinical trial of aripiprazole (with the exception of Investigator Sponsored Trials).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03487770

Layout table for location information
China, Beijing
6th affiliated hospital, Peking University
Beijing, Beijing, China, 100191
Sponsors and Collaborators
Otsuka Beijing Research Institute
Layout table for investigator information
Study Director: Patyman Juma Otsuka Beijing Research Institute

Layout table for additonal information
Responsible Party: Otsuka Beijing Research Institute Identifier: NCT03487770    
Other Study ID Numbers: 031-403-00106
First Posted: April 4, 2018    Key Record Dates
Last Update Posted: January 22, 2020
Last Verified: January 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Otsuka Beijing Research Institute:
Aripiprazole Oral Solution
Additional relevant MeSH terms:
Layout table for MeSH terms
Autistic Disorder
Autism Spectrum Disorder
Child Development Disorders, Pervasive
Neurodevelopmental Disorders
Mental Disorders
Pharmaceutical Solutions
Antidepressive Agents
Psychotropic Drugs
Antipsychotic Agents
Tranquilizing Agents
Central Nervous System Depressants
Physiological Effects of Drugs
Dopamine Agonists
Dopamine Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin Agents
Serotonin 5-HT2 Receptor Antagonists
Serotonin Antagonists
Dopamine D2 Receptor Antagonists
Dopamine Antagonists